A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)

Ki vehet részt

• Completion of the 52-week treatment period in an astegolimab parent study

Ki nem vehet részt

• Any permanent discontinuation of study drug in parent study
• Any new clinically significant pulmonary disease other than COPD (e.g., pulmonary fibrosis, sarcoidosis, chronic pulmonary embolism or primary pulmonary hypertension, alpha-1-antitrypsin deficiency) since enrolling in the parent study
• Any new unstable cardiac disease, myocardial infarction, or New York Heart Association Class III or IV heart failure since enrolling in the parent study
• Withdrawal of consent and/or premature discontinuation from parent study
• Significant non-compliance in the parent study, specifically defined as missing scheduled visits, per investigator's judgment
• Any new diagnosis of asthma according to the Global Initiative for Asthma guidelines or other accepted guidelines since enrolling in the parent study